Regeneron Pharmaceuticals, Inc. $REGN Holdings Decreased by Blair William & Co. IL

Blair William & Co. IL trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,257 shares of the biopharmaceutical company’s stock after selling 25 shares during the quarter. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth $660,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 31 shares during the last quarter. Activest Wealth Management boosted its position in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Finally, Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.3%

NASDAQ:REGN opened at $569.17 on Friday. The firm has a market capitalization of $60.33 billion, a price-to-earnings ratio of 14.34, a PEG ratio of 1.85 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,013.09. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $574.34 and its 200 day moving average price is $563.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $11.56 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Analyst Ratings Changes

Several analysts have recently weighed in on REGN shares. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a report on Monday, August 4th. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Finally, Guggenheim upped their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.